Leidos Awarded $318 Million Defense Health Agency Contract For MHS GENESIS Support
Leidos (LDOS) won a $318M contract from the Defense Health Agency to support MHS GENESIS, the DoD's electronic health record system. The 12-month contract, starting July 2026, covers system reintegration, software licensing, and hosting services. The agency aims to transition some work to other contractors during this period.
How this was made

The 30-second read
Why it matters
The award secures a near‑term revenue stream and may improve Leidos' win‑rate for future defense health contracts.
Market read
A new $318 M contract to a mid‑cap defense contractor is material news that could lift the stock.
What to watch
Potential competition from other contractors during the transition period could limit upside.
Background
Leidos (LDOS) is a major U.S. defense and intelligence contractor. The Defense Health Agency's MHS GENESIS is the DoD's electronic health record system.
Ticker impact
Leidos was awarded a $317,986,855 firm‑fixed‑price contract by the Defense Health Agency to support MHS GENESIS.
likely upward pressure as the market prices in the new multi‑hundred‑million contract.
Large, sole‑source award to a mid‑cap defense contractor; revenue boost expected in FY2027.
Market effects
Boosts outlook for defense IT and government contracting sector.
Positive for U.S. defense contractors and related supply chain.
Limited to defense and health‑record technology niche.
Counterpoint
If the contract is a bridge award with decreasing scope, the long‑term revenue impact may be modest.
Key entities
- CompanyLeidos
U.S. defense and intelligence contractor (ticker LDOS).
- Government AgencyDefense Health Agency
U.S. DoD agency overseeing military health services.


